communityacquir
pneumonia
cap
one
import
infecti
diseas
problem
unit
state
today
account
major
morbid
mortal
approxim
million
ambulatori
care
visit
unit
state
estim
million
hospit
pneumonia
averag
length
stay
day
cap
account
enorm
health
care
cost
estim
billion
price
tag
annual
unit
state
unfortun
past
year
improv
broadspectrum
antibiot
implement
diagnost
studi
declin
patient
etiolog
pathogen
cap
identifi
partial
advanc
antimicrobi
agent
treat
cap
result
lack
perceiv
need
know
etiolog
pathogen
unless
patient
respond
empir
therapi
import
consider
diagnosi
cap
age
immun
state
patient
sever
fatal
diseas
occur
elderli
immunocompromis
young
individu
condit
affect
cardiopulmonari
function
syndrom
caus
multipl
type
organ
may
etiolog
indistinguish
present
elderli
repres
import
factor
rapid
diagnosi
cap
especi
older
gener
increas
unit
state
center
diseas
control
prevent
cdc
statist
indic
although
pneumonia
rate
decreas
hospit
age
group
older
year
still
repres
vulner
popul
fig
hospit
rate
pneumonia
per
popul
decreas
total
popul
rate
decreas
among
age
year
among
age
year
among
age
year
older
howev
throughout
period
rate
hospit
year
older
highest
wherea
younger
year
age
group
substanti
lower
rate
age
group
thu
accur
rapid
diagnosi
cap
import
appropri
patient
manag
especi
elderli
diagnosi
etiolog
agent
cap
depend
use
rapid
assay
sensit
specif
rapid
identif
virus
bacteria
caus
cap
enhanc
appropri
use
antivir
agent
prevent
overus
antibiot
thu
abl
diagnos
respiratori
virus
bacteri
pathogen
integr
part
patient
manag
today
era
cost
contain
antibioticspar
paradigm
cap
respiratori
infect
bacteri
origin
sever
new
molecular
platform
exist
today
identif
respiratori
virus
new
broadbas
platform
horizon
diagnosi
virus
bacteria
fungi
although
accur
diagnosi
highli
desir
perhap
import
rapid
diagnosi
etiolog
agent
cap
affect
immedi
patient
manag
rapid
identif
viral
agent
prevent
use
unnecessari
antibiot
reduc
cost
facilit
time
effect
use
antivir
drug
viral
etiolog
influenza
ultim
may
shorten
hospit
stay
varieti
virus
bacteria
respons
cap
platform
accur
identifi
multipl
agent
ideal
addit
singl
pointofcar
poc
molecular
assay
rapidli
rule
rule
common
agent
influenza
streptococcu
pneumonia
also
desir
immedi
manag
cap
real
question
optim
rapid
patient
care
howev
whether
etiolog
agent
cap
bacteri
viral
bacteri
whether
gramposit
gramneg
answer
real
time
direct
agentspecif
therapi
avoid
overus
preciou
broadspectrum
antibiot
polymeras
chain
reaction
pcr
molecular
test
develop
past
year
coexist
routin
microbiolog
cultur
wide
adopt
contribut
littl
rapid
decis
make
patient
care
especi
bacteria
mani
laboratorydevelop
test
ldt
food
drug
administr
fda
clear
commerci
avail
urinari
pathogen
nonmolecular
fdaclear
diagnost
assay
pneumonia
legionella
except
result
rapidli
avail
singlepathogen
molecular
test
test
requir
suspicion
particular
pathogen
develop
multiplepathogen
molecular
assay
particularli
virus
tool
advanc
pathogendirect
therapi
may
exist
articl
focus
recent
develop
molecular
multiplex
diagnost
assay
platform
mani
fdaclear
use
enhanc
improv
manag
cap
provid
overview
fdaclear
rapid
nonmolecular
test
compar
new
rapid
molecular
test
diagnosi
influenza
respiratori
virus
bacteria
less
emphasi
molecular
test
fdaclear
offer
clinician
less
acut
medic
manag
tool
except
research
studi
mani
fdaclear
nonclear
assay
also
recent
review
great
detail
elsewher
requir
molecular
assay
affect
patient
care
advanc
molecular
diagnost
method
improv
manag
cap
dictat
result
rapid
accur
capabl
detect
multipl
pathogen
one
assay
minimum
assaysrapid
poc
assay
especi
attract
almost
imper
infecti
diseas
societi
americaamerican
thorac
societi
guidelin
recommend
import
therapi
hospit
patient
soon
possibl
first
antibiot
dose
given
emerg
depart
ed
guidelin
drive
rapidli
molecular
test
perform
return
clinician
ed
even
molecular
test
avail
time
initi
therapi
definit
diagnosi
etiolog
agent
molecular
test
promot
quickli
switch
pathogendirect
antibiot
antivir
therapi
cultur
still
may
complet
accuraci
imper
requir
fda
clearanc
achiev
fdaclear
assay
great
advantag
ldt
undergon
extens
clinic
analyt
valid
perform
characterist
well
document
reagent
standard
use
engend
confid
qualiti
assur
accuraci
result
abil
detect
multipl
pathogen
simultan
one
assay
major
impact
manag
cap
menu
etiolog
agent
grown
newli
recogn
organ
newli
emerg
agent
sever
acut
respiratori
syndrom
human
metapneumonviru
hmpv
bordetella
pertussi
new
variant
influenza
even
combin
sever
rapid
test
major
impact
type
therapi
institut
narrow
agentdirect
antibiot
therapi
pneumonia
case
posit
urinari
antigen
test
antivir
therapi
influenza
viru
diagnos
poc
rapid
test
histor
addit
tradit
gram
stain
bacteri
cultur
sputum
nasopharyng
swab
diagnosi
cap
nonmolecular
molecular
assay
molecular
assay
develop
sever
rapid
nonmolecular
method
call
rapid
antigen
direct
test
radt
detect
influenza
addit
nonmolecular
assay
direct
fluoresc
antibodi
dfa
test
use
monoclon
antibodi
direct
patient
viral
transport
cultur
sediment
use
rapid
identif
influenza
virus
still
popular
molecular
test
influenza
virus
use
fdaclear
subject
advanc
diagnos
except
sever
newer
one
mycobacterium
tuberculosi
includ
recent
fdaclear
filmarray
idaho
technolog
salt
lake
citi
ut
mycoplasma
pneumonia
chlamydia
pneumonia
b
pertussi
mani
nonfda
clear
assay
ldt
use
mostli
limit
research
studi
actual
use
manag
cap
nonmolecular
molecular
fdaclear
assay
one
valuabl
patient
care
radt
influenza
fdaclear
radt
highli
variabl
sensit
specif
depend
viral
target
age
patient
sampl
collect
durat
symptom
test
gener
radt
perform
better
test
pediatr
sampl
children
shed
higher
titer
viru
longer
time
period
adult
radt
also
perform
better
period
high
preval
influenza
season
perform
well
detect
pandem
swine
virus
chartrand
colleagu
recent
provid
excel
metaanalysi
describ
perform
studi
report
pool
sensit
specif
perform
better
influenza
influenza
b
fdaclear
radt
avail
commerci
five
clinic
laboratori
improv
amend
clia
waiv
two
detect
distinguish
influenza
b
develop
cliawaiv
assay
increas
accuraci
better
abil
accur
differenti
influenza
type
subtyp
improv
use
clinic
manag
decis
cap
direct
fluoresc
antibodi
rapid
dfa
test
centrifug
sediment
nasopharyng
swab
viral
transport
media
readili
detect
seven
common
respiratori
virus
adenoviru
influenza
b
parainfluenza
viru
piv
respiratori
syncyti
viru
rsv
addit
dfa
test
detect
hmpv
specif
dfa
test
high
sensit
vari
low
compar
nucleic
acid
amplif
test
naat
dfa
test
perform
littl
minut
use
ideal
poc
test
laboratori
locat
near
clinic
order
test
skill
microscopist
requir
thu
use
limit
perform
clinic
laboratori
although
seven
virus
respons
larg
number
respiratori
tract
infect
virus
also
import
caus
respiratori
diseas
includ
bocaviru
select
coronavirus
piv
rhinoviru
detect
use
pcr
naat
type
dfa
diagnost
hybrid
method
diagnost
hybrid
athen
oh
consist
stain
cell
pellet
respiratori
sampl
nasopharyng
swab
sampl
liquid
transport
media
centrifug
monoclon
antibodi
mixtur
pool
antibodi
seven
virus
influenza
b
rsv
piv
adenoviru
anoth
cell
spot
stain
monoclon
hmpv
pool
stain
posit
fluoresc
microscopi
cell
pellet
stain
individu
monoclon
determin
viru
stain
pool
effici
rapid
hour
costeffect
method
screen
respiratori
sampl
neg
disadvantag
fluoresc
microscop
skill
microscopist
requir
sensit
approxim
specif
excel
skill
laboratori
advantag
neg
sampl
screen
one
pool
singl
microscop
visual
screen
pool
reagent
difficult
use
poc
test
unless
laboratori
close
proxim
ed
clinic
liquid
dfa
test
avail
call
fastpoint
quidel
athen
oh
use
three
monoclon
antibodi
cocktail
detect
eight
virus
method
requir
read
three
cell
spot
two
filter
sampl
take
longer
screen
one
pool
disadvantag
piv
distinguish
piv
label
phycoerythrin
nonpoc
fdaclear
molecular
assay
multiplex
pcr
assay
five
fdaclear
multiplex
realtim
revers
transcriptas
rt
pcr
assay
genprob
prodess
madison
wi
qualit
detect
identif
respiratori
virus
influenza
hmpv
piv
adenovirus
tabl
assay
intend
use
clia
highcomplex
laboratori
assay
target
matrix
gene
influenza
nonstructur
gene
influenza
b
polymeras
gene
rsv
rsv
b
assay
subtyp
influenza
sampl
qualit
multiplex
realtim
rtpcr
assay
target
nucleoprotein
gene
influenza
specif
hemagglutinin
gene
season
influenza
season
influenza
intern
control
phage
pro
assay
target
highli
conserv
region
nucleocapsid
n
gene
hmpv
transcript
deriv
escherichia
coli
bacteriophag
aprotein
gene
intern
control
assay
target
conserv
region
hemagglutininneuraminidas
gene
piv
transcript
deriv
e
coli
bacteriophag
aprotein
gene
intern
control
assay
target
hexon
gene
detect
adenoviru
subtyp
f
five
assay
approv
test
nasopharyng
swab
specimen
obtain
symptomat
person
nucleic
acid
extract
use
magna
pure
lc
instrument
roch
diagnost
indianapoli
indiana
magna
pure
total
nucleic
acid
isol
kit
roch
nuclisen
easymag
system
autom
magnet
extract
reagent
rieux
marci
franc
purifi
nucleic
acid
amplifi
mean
rtpcr
use
targetspecif
oligonucleotid
primer
taqman
probe
complementari
highli
conserv
region
target
gene
pcr
cycl
fluoresc
intens
monitor
realtim
instrument
smartcycl
ii
cepheid
sunnyval
ca
time
result
includ
extract
hour
test
run
sensit
specif
detect
influenza
respect
influenza
b
respect
rsv
respect
pediatr
nasopharyng
sampl
result
detect
respiratori
virus
specimen
neg
convent
method
compar
filmarray
respiratori
panel
pro
assay
shown
sensit
specif
compar
xtag
luminex
molecular
diagnost
austin
tx
respiratori
viru
panel
rvp
assay
pro
assay
sensit
demonstr
rang
piv
piv
piv
respect
clinic
trial
specif
higher
xtag
rvp
xtag
rvp
first
multiplex
naat
receiv
clearanc
fda
januari
origin
fdaapprov
version
rvp
detect
adenoviru
influenza
subtyp
season
influenza
season
influenza
influenza
b
piv
hmpv
rhinoviru
rsv
b
approv
use
nasopharyng
swab
symptomat
person
current
rvp
fdaapprov
multiplex
rtpcr
assay
manufactur
luminex
toronto
canada
detect
viral
target
singl
specimen
influenza
influenza
subtyp
influenza
subtyp
influenza
b
rsv
b
piv
hmpv
rhinoviru
adenoviru
fdaclear
nasopharyng
swab
nasal
wash
bronchoalveolar
lavag
sampl
requir
roughli
hour
process
run
assay
secondgener
assay
call
rvp
fast
luminex
avail
europ
fdaclear
unit
state
reduc
number
step
time
result
hour
assay
intend
use
clia
highcomplex
laboratori
shown
highli
sensit
specif
respiratori
virus
compar
filmarray
respiratori
panel
respiratori
viru
plu
verigen
respiratori
viru
nucleic
acid
test
firstgener
verigen
respiratori
viru
nucleic
acid
test
nanospher
northbrook
il
clear
fda
may
test
replac
autom
verigen
respiratori
viru
nucleic
acid
test
sp
clia
moder
complex
test
microarraybas
sampletoresult
fdaclear
identif
influenza
influenza
role
newer
molecular
test
manag
cap
b
type
flu
flu
flu
b
inclus
rsv
b
nasopharyng
swab
specimen
place
viral
transport
media
verigen
system
consist
two
instrument
fulli
autom
verigen
processor
verigen
reader
singleus
test
cartridg
random
access
work
flow
entir
test
process
requir
one
user
pipet
step
less
minut
technic
handson
time
sampletoresult
turnaround
time
hour
test
sensit
specif
detect
influenza
respect
influenza
b
respect
rsv
respect
assay
clia
moder
complex
train
laboratori
technician
must
perform
test
adequ
smallto
mediums
laboratori
limit
assay
includ
singletest
format
requir
dedic
processor
sampl
hour
mutat
oseltamivir
resist
panel
avail
outsid
unit
state
ideal
influenza
poc
diagnost
would
necess
combin
sensit
specif
rtpcr
high
complex
requir
experienc
highli
skill
staff
batch
lower
clinic
use
rapid
simplic
rapid
antigen
test
two
fdaclear
amplifi
molecular
assay
consid
true
poc
requir
approxim
hour
perform
thu
could
potenti
use
initi
patient
manag
decis
concert
diagnost
test
although
filmarray
test
virus
sever
bacteri
pathogen
genexpert
system
detect
influenza
viru
filmarray
technolog
filmarray
system
combin
nucleic
acid
extract
nest
pcr
detect
data
analysi
singleus
pouch
autom
system
enabl
detect
numer
viral
bacteri
respiratori
pathogen
singl
test
requir
reagent
assay
enclos
singleus
pouch
water
ad
hydrat
lyophil
reagent
respiratori
specimen
ad
pouch
load
filmarray
instrument
remaind
test
complet
autom
extract
nucleic
acid
nest
pcr
reaction
perform
within
pouch
entir
close
system
firststep
pcr
multiplex
reaction
contain
primer
viral
bacteri
target
amplicon
first
pcr
dilut
second
round
pcr
reaction
perform
multiwel
array
well
contain
singl
primer
set
target
specif
pathogen
amplif
melt
curv
analysi
allow
filmarray
softwar
gener
result
target
system
robust
detect
low
concentr
pathogen
presenc
high
concentr
second
pathogen
result
avail
hour
compar
laboratorydevelop
realtim
pcr
assay
detect
variou
respiratori
virus
certain
bacteri
pathogen
total
frozen
archiv
pediatr
respiratori
specimen
previous
character
either
neg
posit
one
pathogen
realtim
pcr
examin
use
filmarray
rp
system
overal
agreement
filmarray
rp
correspond
realtim
pcr
assay
share
analyt
kappa
ci
rand
colleagu
compar
filmarray
rp
xtag
rvp
multiplex
respiratori
viru
pcr
method
detect
respiratori
virus
set
patient
specimen
frozen
c
standard
viral
cultur
antigen
detect
method
perform
system
detect
virus
tradit
method
mostli
rhinovirus
hmpv
filmarray
rp
detect
significantli
total
virus
either
alon
part
mix
infect
xtag
rvp
addit
rsv
xtag
rvp
requir
hour
hour
handson
time
wherea
filmarray
rp
took
hour
minut
handson
time
fifteen
virus
detect
differenti
includ
influenza
sensit
rang
adenoviru
mani
virus
nearli
perfect
specif
abil
detect
multipl
pathogen
hour
simpl
setup
fulli
autom
system
offer
signific
benefit
user
friendli
minut
labor
involv
could
eventu
allow
poc
test
ed
outpati
clinic
minim
train
health
care
worker
especi
assay
becom
clia
waiv
time
assay
hour
test
time
great
advanc
test
limit
singl
patient
test
per
run
thu
low
throughput
could
signific
drawback
laboratori
receiv
larg
number
specimen
singl
sampl
process
time
one
instrument
genexpert
system
cepheid
genexpert
system
platform
influenza
ondemand
molecular
diagnost
assay
fulli
integr
system
rapid
sophist
genet
test
organ
geneticbas
diseas
autom
otherwis
complex
manual
laboratori
procedur
easytous
system
integr
sever
complic
timeintens
step
includ
sampl
prepar
dna
amplif
detect
enabl
analysi
influenza
sampl
singl
proprietari
test
cartridg
close
selfcontain
cartridgebas
random
access
assay
perform
nucleic
acid
extract
pcr
amplif
realtim
detect
pcr
product
intermedi
samplehandl
step
autom
platform
repres
paradigm
shift
autom
molecular
analysi
produc
accur
result
time
manner
minim
risk
contamin
assay
first
releas
fda
emerg
use
author
rule
pandem
detect
influenza
includ
pdm
genexpert
emerg
use
author
assay
demonstr
sensit
influenza
compar
cdc
rrtpcr
assay
compar
luminex
xtag
respiratori
viru
rrtpcr
panel
genexpert
sensit
detect
influenza
addit
demonstr
sensit
detect
compar
focu
diagnost
influenza
rrtpcr
assay
newer
version
xpert
flu
second
gener
develop
subsequ
identif
pdm
assay
cartridg
demonstr
overal
sensit
detect
influenza
b
one
studi
sensit
influenza
b
respect
anoth
compar
laboratorydevelop
rrtpcr
assay
test
laboratorydevelop
rrtpcr
assay
xpert
flu
show
sensit
influenza
influenza
b
contrast
secondgener
xpert
flu
test
show
excel
sensit
sensit
influenza
b
respect
compar
commerci
avail
fdaclear
genprob
rrtpcr
dimaio
colleagu
tabl
test
perform
use
three
easi
step
transfer
ml
prepar
sampl
larg
cartridg
open
dispens
elut
reagent
small
open
insert
cartridg
start
assay
advantag
fdaclear
meet
requir
accur
poc
test
influenza
poc
assay
clinic
ed
outpati
set
poc
assay
could
eventu
allow
poc
test
clinic
minim
train
health
care
worker
assay
becom
clia
waiv
pandem
influenza
viru
includ
season
influenza
b
identifi
one
two
four
sampl
run
simultan
sampl
run
larger
random
access
equip
use
test
time
approxim
hour
disadvantag
influenza
b
identifi
differenti
virus
identifi
genexpert
system
combin
onboard
sampl
prepar
realtim
pcr
amplif
detect
function
fulli
integr
autom
nucleic
acid
analysi
system
design
purifi
concentr
detect
identifi
target
nucleic
acid
sequenc
therebi
deliv
answer
directli
unprocess
sampl
modular
design
genexpert
system
varieti
configur
singl
test
format
random
access
sampl
robot
meet
broad
rang
test
demand
clinic
environ
studi
requir
determin
use
variou
test
algorithm
costeffect
allow
rapid
accur
diagnosi
treatment
influenzainfect
patient
poc
set
field
rapidli
emerg
mostli
involv
assay
multiplex
assay
recent
review
detail
caliendo
may
soon
achiev
fda
clearanc
evalu
advantag
manag
cap
novel
molecular
approach
identif
nearli
human
respiratori
viral
pathogen
directli
clinic
patient
specimen
pcrelectrospray
ioniz
mass
spectrometri
ibi
bioscienc
carlsbad
ca
abbott
molecular
desplain
il
potenti
revolution
diagnost
virolog
yet
fdaclear
platform
involv
nucleic
acid
extract
rtpcr
pcr
use
set
primer
target
highli
conserv
gene
flank
variabl
genom
region
follow
inject
amplicon
electrospray
ioniz
timeofflight
mass
spectromet
mass
number
nucleic
measur
excel
review
literatur
discuss
advantag
limit
rel
new
platform
publish
thu
far
sever
public
point
usabl
identif
broad
rang
viral
respiratori
pathogen
sever
format
avail
addit
one
common
respiratori
virus
includ
specif
rapid
influenza
type
h
n
type
platform
instrument
identifi
character
influenza
strain
fda
clearanc
may
come
soon
influenza
type
resplex
technolog
qiaplex
technolog
qiagen
gaithersburg
md
use
pcr
extract
nucleic
acid
follow
liquidphas
beadbas
array
technolog
secondgener
assay
call
resplex
ii
detect
virus
compar
convent
virolog
pcrelectrospray
ioniz
mass
spectrometri
assay
assay
perform
well
detect
virus
convent
virolog
highli
complex
assay
multipl
step
includ
postamplif
handl
sampl
increas
potenti
contamin
system
autogenom
use
multiplex
rtpcr
primer
virus
autom
microarray
hybrid
requir
hour
first
result
specimen
one
evalu
compar
singl
realtim
virusspecif
demonstr
overal
concord
system
handi
lab
acquir
becton
dickinson
diagnost
becton
dickinson
spark
md
use
autom
nucleic
acid
extract
realtim
pcr
multipl
respiratori
pathogen
requir
hour
sampl
detect
influenza
ab
rsv
demonstr
sensit
respect
although
advanc
molecular
diagnosi
cap
pcr
area
viral
infect
less
develop
assay
bacteri
infect
fdaclear
commerci
avail
outstand
one
mostli
tuberculosi
howev
area
nonfdaclear
research
studi
mani
assay
develop
especi
pneumococcu
use
laboratori
ldt
howev
ldt
wide
avail
less
use
practic
clinician
becom
commerci
avail
commerci
fda
clearanc
molecular
amplifi
assay
bacteria
rapidli
take
place
assay
soon
avail
practic
clinician
manag
cap
one
outstand
success
stori
molecular
amplif
import
worldwid
respiratori
pathogen
mycobacteria
view
lack
poor
sensit
acidfact
smear
result
expens
complex
cultur
method
take
week
identif
develop
fdaclear
molecular
test
play
import
role
improv
patient
outcom
cdc
recommend
naat
use
least
one
respiratori
sampl
patient
suspect
tuberculosi
sever
fdaclear
assay
choos
amplicor
mycobacterium
tuberculosi
test
amplicor
roch
diagnost
amplifi
mycobacterium
tuberculosi
direct
test
genprob
san
diego
ca
xpert
mtbrif
cepheid
sunneyval
ca
detect
tuberculosi
rifampin
resist
directli
clinic
specimen
approxim
hour
allow
nucleic
acid
extract
within
cartridg
low
complex
demonstr
high
sensit
compar
standard
methodolog
tabl
mycoplasma
pneumonia
chlamydia
pneumonia
bordetella
pertussi
pneumonia
c
pneumonia
b
pertussi
recent
fdaclear
filmarray
one
publish
articl
mention
detect
one
pneumonia
organ
evalu
viral
pathogen
expect
fda
clearanc
organ
greatli
enhanc
understand
role
play
cap
near
futur
tabl
although
aureu
usual
consid
mostli
hospitalacquir
caus
pneumonia
recogn
common
caus
cap
especi
methicillinresist
aureu
mrsa
fda
clear
sever
pcr
test
detect
mrsa
nasal
swab
specimen
howev
clear
assay
detect
mrsa
methicillinsensit
aureu
agent
cap
sever
poc
assay
clear
screen
use
nasalnar
swab
sensit
sensit
provid
result
less
hour
also
evalu
skin
soft
tissu
blood
cultur
fda
clear
verigen
platform
verigen
gp
blood
cultur
nucleic
acid
test
june
identif
gramposit
bacteria
posit
blood
cultur
advanc
develop
naat
pcr
last
two
decad
offer
huge
understand
diagnost
capabl
assay
manag
cap
develop
research
assay
pave
way
commerci
fda
clearanc
rapidli
take
place
today
notabl
nonfda
clear
assay
includ
one
atyp
agent
c
pneumonia
pneumonia
legionella
pneumophilia
chlamydia
pneumonia
multipl
inhous
nucleic
acid
amplif
pcr
methodolog
publish
literatur
confound
lack
standard
valid
cdc
workshop
identifi
assay
consid
valid
enough
use
research
studi
other
develop
use
advantag
assay
sensit
decreas
possibl
contamin
abil
quantifi
dna
pcr
assay
recent
use
identifi
outbreak
cap
among
navi
seal
research
use
fdaclear
assay
necessari
understand
role
c
pneumonia
cap
extens
studi
realtim
pcr
cap
studi
test
sampl
compar
nest
pcr
touchdown
enzym
timereleas
pcr
demonstr
increas
sensit
compar
tradit
pcr
method
previous
never
commerci
avail
naat
assay
develop
recent
filmarray
lcx
researchuseonli
pcr
develop
abbott
laboratori
use
multicent
studi
comparison
pcr
result
use
inhous
pcr
five
differ
laboratori
perform
well
never
taken
trial
becton
dickinson
perform
clinic
trial
strand
displac
amplif
assay
sda
clear
fda
mani
assay
develop
detect
mycoplasma
report
work
well
especi
outbreak
situat
becton
dickinson
perform
clinic
trial
sda
clear
fda
previous
never
fdaclear
commerci
avail
naat
assay
develop
recent
filmarray
sever
pcr
assay
publish
review
murdoch
becton
dickinson
perform
clinic
trial
sda
clear
fda
never
commerci
mani
research
assay
develop
pcr
amplif
pneumococcu
thu
far
none
fdaclear
one
main
problem
use
assay
sputa
nasopharyng
swab
oropharyng
swab
interpret
result
sensit
assay
also
detect
pneumococc
carriag
seriou
infect
evolut
nonclear
pcr
assay
challeng
interpret
assay
discuss
excel
review
blaschk
earli
assay
target
pneumolysin
gene
show
rather
poor
sensit
specif
crossreact
viridian
streptococci
comparison
sever
gene
target
pcr
indict
autolysi
lyt
gene
specif
target
sheppard
colleagu
demonstr
specif
target
clinic
sampl
progress
made
regard
distinguish
carriag
colon
pneumonia
detect
colon
densiti
use
realtim
pcr
multiplex
pcrelectrospray
ioniz
mass
spectrometri
platform
bacteria
novel
approach
identif
nearli
human
bacteri
pathogen
directli
clinic
patient
specimen
potenti
revolution
diagnost
bacteriolog
yet
fdaclear
excel
review
literatur
discuss
advantag
limit
rel
new
platform
cover
thousand
bacteria
requir
design
specif
agent
test
target
recent
publish
newli
recogn
biomark
assay
neither
diagnost
molecular
deserv
mention
consider
cap
procalcitonin
test
blood
level
procalcitonin
elev
patient
bacteri
infect
sepsi
bacteri
agent
shock
although
thorough
discuss
beyond
scope
articl
need
mention
new
tool
consider
rapid
diagnost
test
make
decis
regard
diagnosi
possibl
bacteri
caus
versu
viral
caus
cap
one
fdaclear
assay
time
biomerieux
assay
make
valuabl
adjunct
clinic
manag
cap
rapid
diagnost
test
avail
potenti
use
assay
review
recent
clinician
want
evalu
use
futur
studi
cap
optim
patient
care
manag
cap
clinician
requir
accur
test
avail
real
time
decis
pathogendirect
antimicrobi
therapi
antivir
therapi
institut
rapidli
antivir
prescrib
etiolog
agent
influenza
present
pathogendirect
therapi
requir
use
assay
fdaclear
highli
accur
complet
time
manner
last
year
greatli
advanc
molecular
nonmolecular
diagnost
assay
routin
care
patient
cap
clinician
assay
meet
requir
includ
research
requir
accur
rapid
assay
avail
especi
fda
clinic
trial
clear
routin
use
comparison
involv
newer
poc
molecular
assay
potenti
influenc
immedi
manag
decis
cap
infecti
diseas
societi
america
state
better
rapid
molecular
diagnost
test
unmet
need
respiratori
tract
infect
fdaclear
assay
especi
need
rapid
diagnosi
pneumonia
research
requir
ascertain
abil
rapid
molecular
identif
genet
marker
predict
antibiot
antivir
resist
may
next
gener
new
assay
research
need
defin
role
highli
multiplex
assay
identifi
hundr
organ
know
implement
especi
light
costcontain
issu
medicin
lastli
clinician
consid
role
antimicrobi
stewardship
improv
outcom
patient
cap
eg
chang
deescal
durat
antimicrobi
whether
molecular
diagnost
tool
play
role
chang
therapi
etiolog
agent
identifi
although
clinician
mani
new
sometim
rapid
molecular
diagnost
tool
result
explos
new
assay
need
use
one
avail
futur
research
advanc
field
etiolog
agent
identif
agent
cap
routin
rather
except
